Telecoms

The provision of communications services and the handling of communications data are subject to extensive EU legislation. This subtopic contains guidance on EU rules relating to telecoms.

The graphic below provides an overview of the telecommunications and digital regulatory framework which applies in the EU.

The EU regulatory framework for electronic communications

In the EU, the provision of electronic communications networks (ECNs) and electronic communications services (ECSs) in each EU Member State was previously governed by a common regulatory framework which originally comprised five directives (the Framework), which are:

  1. Directive 2002/21/EC of 7 March 2002 on a common regulatory framework for electronic communications networks and services as amended by Directive 2009/140/EC (Framework Directive)

  2. Directive 2002/20/EC of 7 March 2002 on the authorisation of electronic communications networks and services as amended by Directive 2009/140/EC (Authorisation Directive)

  3. Directive 2002/19/EC of 7 March 2002 on access to, and interconnection of, electronic communications networks and associated facilities as amended by Directive 2009/140/EC (Access Directive)

  4. Directive 2002/22/EC of 7 March 2002 on universal service and users' rights relating to electronic communications networks and services as amended by Directive 2009/136/EC

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest EU Law News

Commission publishes updated clinical trials guidance package

The European Commission's Directorate-General for Health and Food Safety has published a comprehensive package of updated clinical trials guidance documents, all endorsed by the Clinical Trials Coordination and Advisory Group (CTAG) on 15 October 2025. The package includes new recommendations on criteria for selecting a reporting Member State under Article 85(2)(c) of the Clinical Trials Regulation, establishing a workshare criterion when proposed reporting Member States decline the role, which occurs in approximately 30% of applications. The Commission has updated its recommendation paper on decentralised elements in clinical trials (Version 02), superseding the December 2022 version, with revised national provision overviews and guidance on informed consent, investigational medicinal product delivery, and remote monitoring. A new recommendation paper addresses frequent issues identified during Part I and Part II assessments, based on feedback from national competent authorities and ethics committees, covering investigational medicinal product dossiers, protocols, and safety reporting. The package also includes revised guidance on auxiliary medicinal products, effective 1 December 2025 for new applications, featuring an updated classification system distinguishing between authorised, modified authorised, and unauthorised auxiliary medicinal products with corresponding application and safety reporting requirements.

View EU Law by content type :

Popular documents